SCHEMBL4152053

SCHEMBL4152053

CCN(CCO)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.47
ADRA2A P08913 4/20 0.47
DRD1 P21728 4/20 0.47
SLC6A4 P31645 4/20 0.47
SLC6A3 Q01959 4/20 0.47
KCNH2 Q12809 4/20 0.47
SLC6A2 P23975 3/20 0.47
HTR2A P28223 3/20 0.47
HRH1 P35367 3/20 0.47
ADRA1A P35348 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 1/20 0.47
OPRK1 P41145 1/20 0.47
CYP2D6 P10635 7/20 0.47
CYP2C19 P33261 3/20 0.47
KDM4E B2RXH2 5/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PPARG P37231 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2132415 0.89 CHRM2 (0.49) CHRM2ADRA2ADRD1SLC6A4SLC6A3
SCHEMBL38660198 0.89 CHRM2 (0.57) CHRM2ADRA2ADRD1SLC6A4SLC6A3
SCHEMBL17484101 0.88 KCNH2 (0.46) CHRM2ADRA2ADRD1SLC6A4SLC6A3
Ethylene SCHEMBL28037648 0.85 CHRM2 (0.46) CHRM2ADRA2ADRD1SLC6A4SLC6A3
SCHEMBL225860 0.85 CYP2D6 (0.52) CHRM2ADRA2ADRD1SLC6A4SLC6A3
SCHEMBL29390583 0.85 CYP2D6 (0.52) CHRM2ADRA2ADRD1SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL28665181 0.83 KDM4E (0.53) CHRM2ADRA2ADRD1SLC6A4SLC6A3
SCHEMBL16491453 0.82 CHRM2 (0.69) CHRM2ADRA2ADRD1SLC6A4SLC6A3
SCHEMBL28037970 0.81 CHRM2 (0.44) CHRM2ADRA2ADRD1SLC6A4SLC6A3
Potassium Ion SCHEMBL1369188 0.81 CHRM2 (0.49) CHRM2ADRA2ADRD1SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149508-A1 Process for the preparation of substituted phenyl ether compounds SANDOZ AG (CH) 2009-06-11 US disclosed
CN-101228128-A A process for the preparation of substituted phenyl ether compounds and rosiglitazone SANDOZ AG (CH) 2008-07-23 CN disclosed
EP-1910294-A1 A PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENYL ETHER COMPOUNDS AND ROSIGLITAZONE Sandoz AG (CH) 2008-04-16 EP disclosed
WO-2007017095-A1 A PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENYL ETHER COMPOUNDS AND ROSIGLITAZONE SANDOZ AG (CH) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149508-A1 Process for the preparation of substituted phenyl ether compounds PPARG, PPARD, PPARA CHRM2 3108/4885ADRA2A 1864/4885DRD1 3705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.